Registry Study of Cerebral Small Vessel Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-11-13

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The incidence of cerebral small vessel disease (CSVD) increases with age, affecting approximately 5% of individuals over 50 years old and nearly all individuals over 90 years old. CSVD is also the most important vascular factor contributing to cognitive decline, with 45% of dementia patients attributed to CSVD. Existing interventions are similar to secondary prevention strategies for cardiovascular and cerebrovascular diseases, and no specific therapies are currently available.

CSVD-related cognitive impairment (CSVDCI) predominantly involves attention, processing speed, and executive functions, with relatively preserved memory function, and may be accompanied by non-cognitive clinical manifestations such as gait disturbances, emotional and behavioral disorders, and bladder dysfunction. Although CSVDCI can be classified under vascular cognitive impairment (VCI), there are certain differences in its clinical manifestations.

In summary, it is necessary to develop more targeted treatments for CSVD. We attempt to establish a "symptom-tongue coating-gut microbiota-imaging" system to provide data support for the subsequent exploration of CSVD treatments based on traditional Chinese medicine (TCM) syndrome differentiation and treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Magnetic Resonance Imaging in Cerebral Small Vessel Disease

NCT05200377

Cerebral Small Vessel Diseases MRI

RECRUITING

Intelligent Analysis and Clinical Validation of Cerebral Small Vessel Disease on Magnetic Resonance Imaging：A Multi-center Study

NCT06667635

Cerebral Small Vessel Disease

NOT_YET_RECRUITING

Imaging the Pathogenesis of Cerebral Small Vessel Disease

NCT05703386

Ischemic Stroke Hypertension Hyperlipidemias +1 more

RECRUITING

Correlation Between Deep Medullary Veins and Cognitive Dysfunction in Cerebral Small Vessel Disease

NCT05715710

Cerebral Small Vessel Disease

RECRUITING

Cognitive Impairment, Retinopathy, and Cerebrovascular Lesions in the Elderly

NCT03542734

Cerebral Small Vessel Diseases Retinopathy Cognitive Dysfunction

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cerebral Small Vessel Diseases Cognitive Impairment Diffusion Tensor Imaging

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patient Gourp

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age above 50 years (including 50-year-old);
2. MRI confirmed the presence of typical imaging changes of CSVD;
3. Voluntary participation in the study and be willing to sign the Informed Consent Form.

Exclusion Criteria

1. Patients with acute ischemic stroke or acute intracranial hemorrhage (e.g., epidural hematoma, subdural hematoma, subarachnoid hemorrhage, intracerebral hemorrhage, etc.) or a history of cerebral infarction (non-lacunar) or intracranial hemorrhage within the past 3 months;
2. Significant non-vascular white matter lesions (e.g., multiple sclerosis, adult-onset leukoencephalopathy, metabolic encephalopathy, etc.);
3. Patients with a history of cognitive impairment due to other causes (e.g., normal pressure hydrocephalus, Alzheimer's disease, Parkinson's disease, multiple sclerosis, encephalitis, etc.);
4. Severe hepatic, renal, or cardiac insufficiency (ALT or AST \>2 times the upper limit of normal, or serum creatinine \>1.5 times the upper limit of normal, or New York Heart Association \[NYHA\] functional class III or IV);
5. Patients with psychiatric disorders that affect study medication administration and evaluation;
6. Contraindications to MRI examination (e.g., claustrophobia, presence of an implantable pacemaker, etc.);
7. Patients unable to comply with follow-up examinations or other study procedures due to residential location or other reasons;
8. Participation in other clinical trial projects.

Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No